# TRANSFORM-1 (NCT04472598)

> Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04472598
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: AbbVie
- Conditions: Myelofibrosis (MF)
- Interventions: Placebo for Navitoclax; Ruxolitinib; Navitoclax
- Enrollment: 252
- Primary outcome: Percentage of Participants With ≥ 35% Reduction From Baseline in Spleen Volume at Week 24 (SVR35W24)

## Indexed commentary on TRANSFORM-1 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- YouTube: 32
- Podcasts: 21
- X threads: 20
- X videos: 1

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=transform-1-nct04472598

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04472598", "email": "<work email>"}; the inbox owner confirms by the emailed link.